 |
The second-generation Taxus Liberte coronary stent system. (Boston Scientific Corp.) |
MASS. MOVERS
Boston Scientific slumps on earnings fall
February 3, 2012
Text size
–
+
Boston Scientific Corp.’s fourth-quarter earnings plunged 55 percent, as the medical device maker saw declining sales in two of its biggest businesses, interventional cardiology and cardiac rhythm management. The Natick company said sales fell 15 percent to $482 million in cardiac rhythm management, which includes pacemakers and surgically implanted defibrillators. Revenue dropped 7 percent to $594 million in interventional cardiology, which includes drug-coated stents. Boston Scientific said it earned $107 million, or 7 cents per share. That compares with $236 million, or 15 cents per share, in the final quarter of 2010.
For more from BostonGlobe.com, sign up or log in below
To continue, please sign up or log in to BostonGlobe.com
Access the full articles and quality reporting of The Boston Globe at BostonGlobe.com
Sign up
Unlimited Access to BostonGlobe.com for 4 weeks for only 99¢.
Are you a Boston Globe home delivery subscriber?
Get FREE access as part of your print subscription.
BostonGlobe.com subscriber
Click to continue reading this article or to log in to BostonGlobe.com.
